Mantle cell lymphoma

Chan Y. Cheah, J.F. Seymour, M.L. Wang

Research output: Contribution to journalReview articlepeer-review

221 Citations (Scopus)


© 2016 by American Society of Clinical Oncology. Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy and autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of maintenance rituximab and bendamustine in older patients. In particular, greater depth of understanding of the molecular pathophysiology of MCL has resulted in an explosion of specifically targeted new efficacious agents. In particular, agents recently approved by the Food and Drug Administration include the proteasome inhibitor bortezomib, immunomodulator lenalidomide, and Bruton's tyrosine kinase inhibitor ibrutinib. We review recent advances in the understanding of MCL biology and outline our recommended approach to therapy, including choice of chemoimmunotherapy, the role of stem-cell transplantation, and mechanism-based targeted therapies, on the basis of a synthesis of the data from published clinical trials.
Original languageEnglish
Pages (from-to)1256-1269
Number of pages14
JournalJournal of Clinical Oncology
Issue number11
Publication statusPublished - 10 Apr 2016


Dive into the research topics of 'Mantle cell lymphoma'. Together they form a unique fingerprint.

Cite this